Skip to main content
Clinical Trials/NCT04718116
NCT04718116
Recruiting
Not Applicable

Management of Postsurgical Pain After Cardiac Operations: Comparison of Tapentadol and Tramadol Analgesia

Aretaieion University Hospital2 sites in 1 country90 target enrollmentNovember 1, 2022

Overview

Phase
Not Applicable
Intervention
Group tapentadol 50 mg
Conditions
Postoperative Pain
Sponsor
Aretaieion University Hospital
Enrollment
90
Locations
2
Primary Endpoint
change from baseline in pain score during coughing
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

The aim of this randomized one-blinded study will be to evaluate the efficacy and tolerability of two different oral doses of tapentadol and compare it to tramadol (an opioid commonly used to treat post-surgical pain) in cardiac surgery patients

Detailed Description

Management of post-surgical pain is a daily challenge for every anaesthetist. Undertreated post-surgical pain can result in cardiovascular, pulmonary and gastrointestinal complications, as well as chronic pain and negative psychological effects. A negative impact may be seen on immune function, coagulation and wound healing. Opioids have been the cornerstone in the treatment of pain after cardiac surgery. However, opioids have a number of adverse effects such as respiratory depression, gastrointestinal alterations, dizziness, delirium, addiction. Tapentadol is a new synthetic opioid with dual mechanism of action. It acts as a mu-receptor agonist, as well as norepinephrine reuptake inhibitor. It is used to treat moderate to severe pain and is associated with fewer adverse effects compared to other opioids. The aim of this randomized one-blinded study will be to evaluate the efficacy and tolerability of two different oral doses of tapentadol and compare it to tramadol (an opioid commonly used to treat post-surgical pain). Patients undergoing cardiac surgery and being discharged from ICU to ward within 30 hours of surgery, will be divided into 3 groups. Group A will receive tapentadol 50mg p.o 3 times daily for two days, group B will receive tapentadol 75 mg p.o 3 times daily for two days and group C will receive tramadol 100 mg p.o 3 times daily for two days. Pain level will be assessed with Numeric Rating Scale (NRS), before drug administration and two hours after drug administration. Overall patient satisfaction will be assessed with Likert scale. Brief Pain Inventory( short form) and DN4 questionnaire will be used to detect chronic pain and neuropathic pain respectively, 3 and 6 months after surgery.

Registry
clinicaltrials.gov
Start Date
November 1, 2022
End Date
December 31, 2024
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Kassiani Theodoraki

Professor of Anesthesiology

Aretaieion University Hospital

Eligibility Criteria

Inclusion Criteria

  • age \<75 years old
  • patients discharged from Intensive Care Unit (ICU) in less than 30 hours
  • elective cardiac surgery

Exclusion Criteria

  • hepatic failure (increased transaminase levels
  • renal failure (creatinine\> 2 mg/dL)
  • emergency surgery (hemorrhage, tamponade, aortic dissection)
  • readmission in ICU
  • treatment with monoaminoxidase inhibitors, selective serotonine reuptake inhibitors or antiepileptics
  • age\>75 years old
  • communication or language barriers
  • Lack of informed consent

Arms & Interventions

tapentadol 50 mg

tapentadol 50mg p.o 3 times daily for two days

Intervention: Group tapentadol 50 mg

tapentadol 75 mg

tapentadol 75 mg p.o 3 times daily for two days

Intervention: group tapentadol 75 mg

tramadol 100 mg

tramadol 100 mg p.o 3 times daily for two days

Intervention: group tramadol 100 mg

Outcomes

Primary Outcomes

change from baseline in pain score during coughing

Time Frame: 2 hours after analgesia administration

pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

side effects

Time Frame: 2 hours after analgesia administration

side effects resulting from analgesic administration, yes or no

incidence of neuropathic pain 3 months after surgery

Time Frame: 3 months after surgery

occurrence of neuropathic pain 3 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire

change from baseline in pain score at rest

Time Frame: 2 hours after analgesia administration

pain score will be assessed by the use of Numeric Rating Scale (NRS) 2 hours after analgesia administration, ranging from 0 to 10, where 0 means "no pain" and 10 means "worst pain imaginable"

incidence of chronic pain 3 months after surgery

Time Frame: 3 months after surgery

occurrence of chronic pain at the site of the operation 3 months after surgery, with the use of the Brief Pain Inventory Questionnaire

incidence of chronic pain 6 months after surgery

Time Frame: 6 months after surgery

occurrence of chronic pain at the site of the operation 6 months after surgery, with the use of the Brief Pain Inventory Questionnaire

incidence of neuropathic pain 6 months after surgery

Time Frame: 6 months after surgery

occurrence of neuropathic pain 6 months after surgery, with the use of the Douleur Neuropathique (DN4) Questionnaire

Secondary Outcomes

  • satisfaction from postoperative analgesia(72 hours postoperatively)
  • hospitalization time(postoperatively, an average period of 10 days)

Study Sites (2)

Loading locations...

Similar Trials